Antidisialosyl antibodies in chronic idiopathic ataxic neuropathy

Serrano-Munuera, Carmen; Rojas‐García, Ricard; Gallardo, Eduard; Luna, Noemí de; Buenaventura, I; Ferrero, Mercedes; García, Teresa; García-Merino, J A; González-Rodríguez, Concepción; Guerriero, A; Marco, María C. de; Márquez, C Haro; Grau, J M; Graus, Francesc; Illa, Isabel

doi:10.1007/s00415-002-0882-2

Cited by 9 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these neuropathies are rare, and series such as this one nevertheless provide useful information about the range of responses to IVIg obtained in patients with these neuropathies. One important clinical aspect to which this study leads, in keeping with previous studies,3 16 17 20 31 is that anti-GD1b antibodies should be measured in all patients with otherwise idiopathic sensory ataxic neuropathies, even in the absence of monoclonal IgM paraprotein or demyelinating features detected at NCS or features of CANOMAD.…”

Section: Discussionsupporting

confidence: 56%

“…Reports of the therapeutic response of patients with GD1b associated sensory neuropathies are even rarer. Plasmapheresis improved in some of the patients treated,1 14 whereas only a few of the patients treated with corticosteroids improved 5 9 11 15 16 17 18 19 20 21. Intravenous immunoglobulin (IVIg) has been used in a few cases,9 16 17 19 21 and half of these patients improved.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy

Attarian

Boucraut

Hubert

et al. 2009

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

Methods: patients with chronic sensory ataxic neuropathy associated with anti-GD1b IgM antibodies followed in our department for at least 12 months between 2001 and 2008 were identified and studied retrospectively. Patients were tested at regular intervals using the INCAT disability score. Patients whose disability scores improved by at least one point were taken to have responded to the treatment. Intravenous immunoglobulin (IVIg; 2 g/kg) was administered for 3 to 5 days once every 6 weeks or corticosteroids at an initial daily dose of 1 mg/kg.

show abstract

Section: Discussionsupporting

confidence: 56%

mentioning

confidence: 99%

Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy

Attarian

Boucraut

Hubert

et al. 2009

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

show abstract

“…Twenty-six individual publications containing descriptions of 64 patients with chronic sensory ataxic neuropathy and anti-disialosyl IgM antibodies were found. This includes the largest case series of 18 patients [4], another series of 13 patients [5], 6 patients who were described within a larger series of 87 patients with neuropathy associated with monoclonal gammopathies [6] and two patients from a case series of 13 patients [7]. The remaining 22 publications are case reports of one or two patients with chronic sensory ataxic neuropathy and anti-disialosyl IgM antibodies [2,.…”

Section: Literature Reviewmentioning

confidence: 99%

A Case of CANOMAD with Review of the Literature

Halpin¹

2015

Brain Disord Ther

View full text Add to dashboard Cite

Introduction: CANOMAD (an acronym for its full manifestation of chronic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl antibodies) is an uncommon paraproteinaemic neuropathy. Methods and Results:We present the case of a man of 58 years at presentation, with chronic ataxic neuropathy, ophthalmoplegia, and an IgM paraprotein who was found to have antibodies active against disialosylgangliosides. Despite treatment trials with a range of immunosuppressive therapies, intravenous immunoglobulin proved the only effective treatment strategy in his case. Conclusions: CANOMAD has been described in a growing number of individual reports and small series for which we have methodically searched the literature. In the absence of randomised trials of treatment for this disabling condition, we bring together these published clinical experiences, describing the degree of heterogeneity in the presentation/laboratory findings and demonstrating that intravenous immunoglobulin is the therapy found most frequently to be successful.

show abstract

“…IgM antibodies to GQ1b have been reported in some patients in whom they were often associated with IgM monoclonal gammopathy ( Ilyas et al, 1985 ; Arai et al, 1992 ; Duane et al, 1992 ; Obi et al, 1992 ; Yuki et al, 1992b ; Willison et al, 1993; 2001 ; Oka et al, 1996 ; Carpo et al, 1998 ; Susuki et al, 2001 ; Serrano‐Munuera et al, 2002 ; Attarian et al, 2010 ) . In most of these patients, IgM was also bound to other gangliosides containing a disialosyl residue including GD3, GD1b, and GT1b.…”

Section: Anti‐ganglioside Antibodiesmentioning

confidence: 99%

Testing for anti‐glycolipid IgM antibodies in chronic immune‐mediated demyelinating neuropathies

Nobile‐Orazio

Giannotta

2011

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Antibodies to several nerve antigens have been reported in patients with chronic immune-mediated demyelinating neuropathies including chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and IgM paraproteinemic demyelinating polyneuropathy. The association of some reactivities with specific neuropathies, such as IgM antibodies to the myelin-associated glycoprotein in neuropathy associated with IgM monoclonal gammopathy, permitted to cast some light in their pathogenetic mechanisms and introduced new useful tools in their diagnosis. Other antibodies have been variably associated with other forms of neuropathy or with neuropathy itself, casting some doubts on their diagnostic relevance in the workout of these neuropathies. This is particularly true for IgM antibodies to glycolipids, including ganglioside and sulfatides, whose possible role in immune-mediated neuropathies is still debated and will be here reviewed.

show abstract

Antidisialosyl antibodies in chronic idiopathic ataxic neuropathy

Cited by 9 publications

References 17 publications

Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy

Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy

A Case of CANOMAD with Review of the Literature

Testing for anti‐glycolipid IgM antibodies in chronic immune‐mediated demyelinating neuropathies

Contact Info

Product

Resources

About